Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.62 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 33.7× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| RXRX | VCIT | |
|---|---|---|
Market Cap | $2.14B | $72.20B |
Volume | 30,789,535 | 14,162,206 |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $84.82 |
52-Week Low | $2.84 | $77.98 |
Typical Hold Time | 22 Days | 61 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
VCIT trades at $78.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with strong selling pressure in moving averages, though oscillators are neutral. The ETF offers a 4.8% yield with a 6-year duration, positioning it as a balanced income option among investment-grade corporate bond ETFs. Recent institutional buying includes Engineers Gate Manager LP's $1.27 million purchase in September 2026.
VCIT presents a compelling risk-return profile for income-focused investors seeking corporate bond exposure. The fund's low 0.03% expense ratio and higher yield compared to treasury alternatives provide value, though interest rate sensitivity and market volatility remain key risks. Analyst sentiment is generally positive given its competitive positioning in the fixed income ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
